Catalyst Pharmaceuticals (CPRX) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free cprx Stock Alerts $15.12 +0.39 (+2.65%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSanthera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in Mayglobenewswire.com - April 25 at 1:00 AMDirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026investorplace.com - April 24 at 1:45 PMCatalyst Pharmaceuticals Inc.barrons.com - April 23 at 2:57 PMCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024globenewswire.com - April 22 at 8:00 AMAllspring Global Investments Holdings LLC Has $2.61 Million Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - April 21 at 4:44 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stake Reduced by Cornercap Investment Counsel Inc.marketbeat.com - April 18 at 6:30 AMCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 3.5%marketbeat.com - April 15 at 1:55 PMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 25,000 Sharesinsidertrades.com - April 11 at 6:37 AMSingle Catalyst Paves the Way for Efficient Drug Synthesismsn.com - April 8 at 1:32 PMCatalyst Pharmaceuticals, Inc.cnn.com - April 7 at 12:33 AMCatalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)seekingalpha.com - April 6 at 7:52 AMVanguard Group Inc. Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - April 6 at 4:15 AMFirst Week of May 17th Options Trading For Catalyst Pharmaceuticals (CPRX)nasdaq.com - April 5 at 12:31 AMShort Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Drops By 9.9%marketbeat.com - April 2 at 11:56 PMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Brokeragesmarketbeat.com - April 1 at 6:14 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Down 9.9% in Marchmarketbeat.com - March 31 at 11:37 PMBrian Elsbernd Sells 25,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stockinsidertrades.com - March 30 at 5:08 AMBrokers Set Expectations for Catalyst Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:CPRX)marketbeat.com - March 29 at 8:38 AMInsider Sell: Chief Compliance/Legal Officer Brian Elsbernd Sells 25,000 Shares of Catalyst ...finance.yahoo.com - March 28 at 9:23 PMInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 25,000 Shares of Stockmarketbeat.com - March 28 at 7:28 PMCatalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Dayglobenewswire.com - March 28 at 8:03 AMDecoding 7 Analyst Evaluations For Catalyst Pharmaceuticalsmarkets.businessinsider.com - March 27 at 10:02 AMCatalyst Pharmaceuticals (NASDAQ:CPRX) Earns Outperform Rating from Oppenheimermarketbeat.com - March 27 at 8:29 AMCatalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposiumglobenewswire.com - March 27 at 8:03 AM3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch Listinvestorplace.com - March 27 at 7:44 AMAmerican Century Companies Inc. Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - March 24 at 4:12 AMInvestors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three yearsfinance.yahoo.com - March 22 at 5:36 PMCatalyst Pharmaceuticals (NASDAQ:CPRX) Receives "Overweight" Rating from Cantor Fitzgeraldmarketbeat.com - March 22 at 2:58 PM7 Biotech Stocks Ready to Ride the Sector's Resurgenceinvestorplace.com - March 18 at 8:01 PMCatalyst Pharmaceuticals' (CPRX) "Overweight" Rating Reiterated at Cantor Fitzgeraldmarketbeat.com - March 18 at 6:00 PMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Sees Large Increase in Short Interestmarketbeat.com - March 16 at 11:04 PMHudson Bay Capital Management LP Acquires 100,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - March 16 at 5:44 AMCPRX Apr 2024 12.500 callfinance.yahoo.com - March 15 at 11:08 PMCPRX Apr 2024 17.500 putfinance.yahoo.com - March 15 at 11:08 PMAnalysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)markets.businessinsider.com - March 14 at 10:04 PMCPRX Apr 2024 20.000 putfinance.yahoo.com - March 14 at 10:04 PMCitigroup Initiates Coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX)marketbeat.com - March 14 at 8:20 AMSanthera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United Statesfinanznachrichten.de - March 14 at 7:02 AMSanthera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United Statesfinance.yahoo.com - March 14 at 7:02 AMSanthera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United Statesglobenewswire.com - March 14 at 2:00 AMCatalyst Pharmaceuticals (NASDAQ:CPRX) Rating Lowered to Hold at StockNews.commarketbeat.com - March 13 at 11:13 PMCatalyst Pharmaceutical Gains Following US Commercial Launch Of Agamreemarkets.businessinsider.com - March 13 at 12:46 PMCatalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)globenewswire.com - March 13 at 7:55 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Position Trimmed by AQR Capital Management LLCmarketbeat.com - March 12 at 5:28 AM3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolioinvestorplace.com - March 10 at 3:24 PMKennedy Capital Management LLC Has $7.44 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - March 7 at 8:31 AMCatalyst Pharmaceuticals (NASDAQ:CPRX) Now Covered by Analysts at Bank of Americamarketbeat.com - March 7 at 8:20 AMResearch Analysts Set Expectations for Catalyst Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:CPRX)marketbeat.com - March 7 at 7:37 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Holdings Trimmed by Invesco Ltd.marketbeat.com - March 6 at 4:59 AM3 Biopharma Stocks You Don't Want to Miss in the New Bull Marketfool.com - March 5 at 9:30 AM Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him CPRX Media Mentions By Week CPRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.720.44▲Average Medical News Sentiment CPRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼54▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNDX News SDGR News GPCR News RNA News NAMS News PTCT News GLPG News GERN News AMPH News HRMY News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
